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International 
Travel and Sexually
Transmitted
Disease 
To the Editor: Recent articles in
the professional literature (1–3) have
offered advice regarding the impor-
tance of taking a careful travel history,
particularly in this time of unprece-
dented levels of international travel
1654 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 9, No. 12, December 2003LETTERS
(4). Such screening serves an impor-
tant public health purpose as well,
especially for sexually transmitted
disease (STD) control. 
Sexual behaviors associated with
travel can change the level of risks for
STD transmission (5–7), and the epi-
demiology of STDs is not uniform
throughout the world (8,9). These
geographic differences may increase
the risk of a traveler’s becoming
infected, or, conversely, increase the
risk of a traveler’s introducing a sexu-
ally transmitted pathogen, possibly
one that is resistant to treatment, into
a low-incidence area (10). In addition,
different strains of pathogens may be
common in different parts of the
world (11–14). For example,
quinolone-resistant  Neisseria gonor-
rhoeae (QRNG) is much more com-
mon in Asia (up to 40% of all isolates)
(15). These strains of QRNG were
first introduced in the United States
by persons who engaged in sexual
activity abroad, but now California
and Hawaii have an increasing inci-
dence of infection attributable to these
strains (16). Indeed, QRNG has
become endemic in those states, and
incidence is no longer related to travel.
During 1999–2001, only 3 QRNG
isolates (0.28%) were identified
among the 1,066 gonococcal isolates
cultured in the STD Laboratory, State
Laboratory Institute, Massachusetts
Department of Public Health
(Massachusetts Department of Public
Health, unpub. data). However, in
2002, 9 (2.1%) of 425 isolates of
Neisseria gonorrhoeae were quino-
lone resistant. None of the persons
recently infected reported a history of
travel outside of New England.
Unfortunately, few had reliable infor-
mation to identify their partner(s).
Those partners who were identified
were either not located or did not
agree to speak with the disease inter-
vention specialist.
This experience with antimicrobial
resistance of Neisseria gonorrhoeae
should serve as a model for STD pre-
vention planning and programming. It
highlights the importance of retaining
the laboratory capacity to monitor
antimicrobial susceptibilities of bacte-
rial STD isolates. Treatment protocols
should be adjusted in light of the
prevalence of resistant strains of sex-
ually transmitted pathogens. In cases
in which symptoms associated with a
bacterial STD persist after what is
usually considered appropriate treat-
ment, clinicians should obtain cul-
tures and perform susceptibility tests
on isolates. Nucleic acid amplification
technologies do not provide critical
antibiotic susceptibility information.
In this situation, the public health
STD program or laboratory should be
contacted for guidance. Determining
the sensitivity pattern of the pathogen
in an expeditious fashion will ensure
that appropriate and timely therapy
can be initiated for the infected patient
as well as enable more effective fol-
low-up and treatment to sexual con-
tacts. Asking patients who seek treat-
ment for a possible STD about their
own and their partner’s travel histo-
ries is important to broaden the differ-
ential diagnosis (17). The increase in
population mixing facilitated by tra-
vel and Internet-generated contacts
may be diminishing the importance of
the focality of traditional STD epi-
demiology. Finally, STD prevention
messages should be a part of the
health advice offered to travelers
(7,18,19).
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Salmonella in
Denmark 
To the Editor: In the large study
by Evans and Wegener recently pub-
lished in Emerging Infectious
Diseases (1), salmonellae in broiler
chickens and pigs significantly
decreased after routine in-feed antimi-
crobial drug use for growth promotion
was terminated in Denmark.
Avoparcin was a frequently used
growth promoter in poultry until its
ban in Denmark in 1995 because of its
association with the development and
spread of vancomycin-resistant ente-
rococci. On examining Evans and
Wegener’s data, I noticed that a pre-
cipitous drop in salmonellae in broiler
chickens appeared to have occurred in
early 1996. Do the authors think this
drop was due to the withdrawal of
avoparcin? As the authors note,
avoparcin has been associated with
increased shedding of salmonellae
(including a dose-response effect) in a
number of studies (2,3). If the large
drop (from approximately 25% posi-
tive samples in 1995 to approximately
10% in 1996) is not due to withdraw-
al of avoparcin, what do the authors
suggest could have caused it? 
Do the authors have sufficient
numbers of samples to reanalyze their
data in broiler chickens for three peri-
ods instead of just two (i.e., use the
periods January 1995–December
1995, January 1996–December 1997,
and January 1998–December 2000)?
This change would take into account
the potential effect of avoparcin with-
drawal in 1995. 
Also, the most important reason
for decreasing food animals’ carriage
of salmonellae is to protect people
from becoming ill with Salmonella.
Do the authors have any figures on
domestically acquired human infec-
tions with salmonellae in Denmark
since early 1995? Is there any tempo-
ral association with the withdrawal of
growth promoters?
Peter Collignon*
*Sydney University, Woden, Australia
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In Reply: The drop in Salmonella
organisms in broiler chickens
becomes evident in September 1995.
The ban on avoparcin occurred in
May 1995. These two facts suggest
that the first flocks of broiler chickens
produced without avoparcin were
slaughtered in August 1995. Thus, the
temporal relationship is evident. We
have reanalyzed the data for the three
strata January 1994–December 1995,
January 1996–December 1997, and
January 1998–December 2000. Each
stratum is significantly different from
the two others (p < 0.0001).
Arguing in favor of a causal rela-
tionship, apart from the temporal rela-
tionship, one would say that no
changes in the Salmonella control
program in this period could explain
this reduction. Arguing against a
causal relationship, one would say
that the levels momentarily bounced
back to nearly the pre-ban level in
1997, despite the avoparcin ban. The
subsequent drop and consistent low
level could be explained by changes
in the control program (introduction
of serologic Salmonella monitoring in
1997 to 1998). On the basis of our
data, drawing a conclusion one or the
other is not possible.
There is a clear temporal associa-
tion between reduction in Salmonella
in broiler chickens and reduced inci-
dence of domestically acquired
Salmonella infections that can be
attributed to domestically produced
broilers. This finding was recently
reported in this journal (1).
Mary E. Patrick* 
and Henrik C. Wegener†
*DeKalb County Board of Health, Decatur,
Georgia, USA; and †Danish Veterinary
Institute, Copenhagen, Denmark 
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